Natco Pharma | Intellepedia

Risdiplam – Spinal Muscular Atrophy Case: Delhi HC Favors Public Health Over Roche Patent

Delhi High Court Denies Injunction on SMA Drug Patent, Prioritises Public Interest Over Patent Rights

The Delhi High Court, in a significant ruling dated March 24th, 2024, rejected the interim injunction application of F Hoffmann-La Roche AG (“Roche”) against Natco...

Revisiting Novartis versus Natco – Cancer drugs, divisional applications and patent validity

The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in force, reinforcing the enforceability of Novartis’s patent rights.

Cancerous Battle: Novartis and NATCO clash over Eltrombopag

The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges and the requirements under Section 3(d) of the Patents Act in pharmaceutical cases.

Kudos Pharma v. Natco Pharma: A case on patent claims, coverage, validity and infringement.

The Delhi High Court’s decision in Kudos Pharma v. Natco Pharma reviews crucial aspects of patent law, including credible challenge and the distinction between patent coverage and disclosure. The Court granted an interim injunction to Kudos Pharma, reinforcing core principles of Indian patent jurisprudence.

CASE BRIEF: FMC Corporation & Ors. vs. Natco Pharma Limited

The Delhi High Court analysed whether Natco Pharma’s process infringed FMC Corporation’s patented method for producing chlorantraniliprole. The court, relying on expert opinions, found key differences in process steps and chemical agents, leading to a decision of non-infringement.

Delhi High Court asks the Patent Office to decide on amendments and give adequate opportunity in Opposition Proceedings

The Delhi High Court has provided clear procedural guidance for patent opposition proceedings, focusing on transparency and fair opportunity for all parties. The judgment underscores the importance of timely decisions on claim amendments and systematic handling of pre-grant oppositions by the Indian Patent Office.

SC extends limitation period again, Natco Pharma obtains patent license from Medicines Patent Pool and other patent news

This week’s patent news highlights the Supreme Court’s extension of limitation periods and Natco Pharma’s new license for Molnupiravir. Updates also include important patent litigation developments in India and globally.

Latest Patent Cases in 2021 – Part 3

This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity, scope, and interim injunctions in Indian pharmaceutical and agricultural sectors.

Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more

Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates in IP law are discussed, including ongoing litigation and international proposals.

Innovate, Patent, Produce and Prosper says PM, Natco Pharma faces patent infringement law suit and more

This bulletin highlights Prime Minister Modi’s emphasis on innovation and patenting, the upcoming GIPC in New Delhi, and crucial legal updates such as Taiho Pharmaceutical’s lawsuit against Natco Pharma. Important decisions from the Indian Patent Office and international appointments are also covered.